Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics (IOVA)
:IOVA
IOVA Analyst Ratings
Moderate Buy
7 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IOVA Stock 12 Month Forecast
Average Price Target
$10.00
▲(491.72%Upside)
| Highest Price Target$25.00 | Average Price Target$10.00 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$2
Hold
18.34%
Upside
Reiterated
06/26/25
Iovance Biotherapeutics' stock score reflects its current growth phase marked by significant revenue increases and strong equity, offset by ongoing losses and cash flow challenges. The technical indicators suggest bearish momentum, while mixed earnings call sentiments and recent corporate events add moderate risk. The valuation is impacted by negative earnings, typical for a company investing heavily in growth.
Goldman Sachs
$16→$8
Buy
373.37%
Upside
Reiterated
06/03/25
Citizens JMP
―
Hold
―
Reiterated
06/03/25
H.C. Wainwright
$20
Buy
1083.43%
Upside
Reiterated
06/03/25
TD Cowen
$5
Buy
195.86%
Upside
Reiterated
06/02/25
Barclays
$4
Buy
136.69%
Upside
Reiterated
06/02/25
Wells Fargo
$18
Buy
965.09%
Upside
Reiterated
06/01/25
UBS
$2
Hold
18.34%
Upside
Downgraded
05/16/25
Truist Financial
$5
Hold
195.86%
Upside
Downgraded
05/12/25
Chardan Capital
$30→$25
Buy
1379.29%
Upside
Reiterated
05/09/25
Robert W. Baird
$20→$3
Hold
77.51%
Upside
Downgraded
05/09/25
Mizuho Securities
$30→$10
Buy
491.72%
Upside
Reiterated
05/09/25
Stifel Nicolaus
$18
Buy
965.09%
Upside
Reiterated
03/17/25
Jefferies
$23→$18
Buy
965.09%
Upside
Reiterated
03/13/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$2
Hold
18.34%
Upside
Reiterated
06/26/25
Iovance Biotherapeutics' stock score reflects its current growth phase marked by significant revenue increases and strong equity, offset by ongoing losses and cash flow challenges. The technical indicators suggest bearish momentum, while mixed earnings call sentiments and recent corporate events add moderate risk. The valuation is impacted by negative earnings, typical for a company investing heavily in growth.
Goldman Sachs
$16→$8
Buy
373.37%
Upside
Reiterated
06/03/25
Citizens JMP
―
Hold
―
Reiterated
06/03/25
H.C. Wainwright
$20
Buy
1083.43%
Upside
Reiterated
06/03/25
TD Cowen
$5
Buy
195.86%
Upside
Reiterated
06/02/25
Barclays
$4
Buy
136.69%
Upside
Reiterated
06/02/25
Wells Fargo
$18
Buy
965.09%
Upside
Reiterated
06/01/25
UBS
$2
Hold
18.34%
Upside
Downgraded
05/16/25
Truist Financial
$5
Hold
195.86%
Upside
Downgraded
05/12/25
Chardan Capital
$30→$25
Buy
1379.29%
Upside
Reiterated
05/09/25
Robert W. Baird
$20→$3
Hold
77.51%
Upside
Downgraded
05/09/25
Mizuho Securities
$30→$10
Buy
491.72%
Upside
Reiterated
05/09/25
Stifel Nicolaus
$18
Buy
965.09%
Upside
Reiterated
03/17/25
Jefferies
$23→$18
Buy
965.09%
Upside
Reiterated
03/13/25
Best Analysts Covering Iovance Biotherapeutics
1 Month
xxx
Success Rate
14/32 ratings generated profit
Average Return
+2.63%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 43.75% of your transactions generating a profit, with an average return of +2.63% per trade.
3 Months
xxx
Success Rate
9/15 ratings generated profit
Average Return
+8.60%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +8.60% per trade.
1 Year
Success Rate
14/32 ratings generated profit
Average Return
+7.40%
reiterated a buy rating 2 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +7.40% per trade.
2 Years
xxx
Success Rate
7/32 ratings generated profit
Average Return
-36.01%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 21.88% of your transactions generating a profit, with an average return of -36.01% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IOVA Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
16
17
15
16
14
Buy
8
4
3
1
1
Hold
2
2
2
6
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
23
20
23
22
Each month's total comprises the sum of three months' worth of ratings.
IOVA Financial Forecast
IOVA Stock Forecast FAQ
What is IOVA’s average 12-month price target, according to analysts?
Based on analyst ratings, Iovance Biotherapeutics’s 12-month average price target is 10.00.
What is IOVA’s upside potential, based on the analysts’ average price target?
Iovance Biotherapeutics has 491.72% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IOVA a Buy, Sell or Hold?
Iovance Biotherapeutics has a consensus rating of Moderate Buy which is based on 7 buy ratings, 5 hold ratings and 0 sell ratings.
What is Iovance Biotherapeutics’s price target?
The average price target for Iovance Biotherapeutics is 10.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $2.00. The average price target represents 491.72% Increase from the current price of $1.69.
The highest analyst price target is $25.00 ,the lowest forecast is $2.00. The average price target represents 491.72% Increase from the current price of $1.69.
What do analysts say about Iovance Biotherapeutics?
Iovance Biotherapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of IOVA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.